TRASTUZUMAB (Herceptin) prior authorization at UPMC Health Plan
Submission criteria, P2P prep, and appeal path if denied — for prescribers and PA staff
UPMC Health Plan requires HER2/neu Receptor Antagonist prior-authorization documentation for TRASTUZUMAB (Herceptin): a diagnosis with ICD-10 code, documented step-therapy history, and prescriber attestation of medical necessity. Standard PA decisions return on the clock printed in the current member-specific payer source; if denied, use the appeal window printed on the denial notice to appeal.
The PA criteria you'll need to meet
UPMC Health Plan reviews TRASTUZUMAB (Herceptin) prior authorizations against its medical policy for HER2/neu Receptor Antagonist. UPMC Health Plan-specific context: Integrated payer-provider arm of UPMC (~4M members). Western PA dominant. The Highmark-UPMC consent decree (expired June 2019) governed cross-network access historically; subsequent commercial agreements maintain some access. PA Insurance Department oversight.
Documentation packet checklist
- Chart note with diagnosis (ICD-10 code) and clinical severity markers
- Documented failure of, contraindication to, or intolerance of step-therapy alternatives in HER2/neu Receptor Antagonist
- Prior treatment history including dosing, duration, and reason for discontinuation
- Relevant labs, imaging, or assessment scores supporting medical necessity
- Prescriber attestation linking the FDA-approved indication to the patient's presentation
- UPMC Health Plan's medical policy URL referenced in the cover letter
Denial scenarios to check against the current policy
These are preparation scenarios, not frequency claims. Use only those supported by the current member-specific source:
- Highmark-vs-UPMC network access disputes (historical PA consent decree)
- Specialty drug PA
- Behavioral health prior auth
- Out-of-network reductions
TRASTUZUMAB (Herceptin)-specific review scenarios and context
Check whether the current notice cites any of these label-, REMS-, or policy-related scenarios:
- Plan-mandated biosimilar switch mid-treatment
- HER2 IHC 2+ with FISH equivocal — plan demands IHC 3+
- Adjuvant duration beyond 1 year
- Site-of-care reduction
Brand: Herceptin. Reference biologic for HER2-positive breast and gastric cancer. Biosimilars: Kanjinti, Trazimera, Ogivri, Ontruzant, Herzuma. Also a component of Enhertu (trastuzumab deruxtecan, separate molecule) and Kadcyla.
Manufacturer patient-assistance program: Genentech Patient Foundation — relevant when an UPMC Health Plan denial sticks and the patient needs bridge access while appealing.
How UPMC Health Plan approaches Biosimilars PAs
For TRASTUZUMAB (ONTRUZANT), check whether the current UPMC Health Plan Biosimilars policy cites specialty drug pa. Pharmacy-benefit review for TRASTUZUMAB (ONTRUZANT) at UPMC Health Plan is routed through UPMC Pharmacy Network (in-house, integrated payer-provider). The applicable review clock depends on the member's current product, whether the request is complete and urgent, and governing plan rules. Confirm receipt and timing with UPMC Health Plan; if denied, use the filing date and route printed on that denial notice. UPMC Health Plan treats interchangeability designation and prescriber "dispense-as-written" language as the two pivot points for biosimilar-vs-reference disputes. UPMC Health Plan is domiciled in PA, so unresolved appeals escalate to the PA insurance department's external-review program for fully-insured policies (self-funded ERISA plans route to the DOL EBSA instead).
If the PA is denied
Verify the appeal window and decision clock in the current denial notice and member-specific payer source before relying on either. Submit through the provider portal (https://www.upmchealthplan.com/providers) with the same packet plus an applicable, current clinical source supporting TRASTUZUMAB (Herceptin)for the patient's indication.
Contact UPMC Health Plan
- Provider portal: https://www.upmchealthplan.com/providers
Frequently asked questions
What documentation does UPMC Health Plan need for TRASTUZUMAB (Herceptin) prior auth?
UPMC Health Plan's typical PA packet for TRASTUZUMAB (Herceptin): (1) chart note documenting the indication and prior-treatment failures, (2) supporting lab/imaging where indicated, (3) prescriber attestation that step-therapy alternatives were tried or contraindicated, (4) FDA-approved indication mapped to ICD-10 diagnosis. For HER2/neu Receptor Antagonist, expect clinical-criteria documentation specific to this class.
What's the turnaround time at UPMC Health Plan?
Verify the decision clock in the current member-specific payer policy and request receipt. Product type, urgency, state law, and plan terms can change the applicable timing; this page does not supply an operational deadline.
What documentation issues should be checked for TRASTUZUMAB (Herceptin) at UPMC Health Plan?
Preparation scenarios to check against the current notice and policy include: Highmark-vs-UPMC network access disputes (historical PA consent decree); Specialty drug PA; Behavioral health prior auth. These are not measured frequency claims. For TRASTUZUMAB (Herceptin), verify whether the actual denial raises step therapy, indication, or another plan-specific criterion before responding.
Can UPMC Health Plan force a mid-treatment switch from the reference biologic to TRASTUZUMAB (ONTRUZANT)?
UPMC Health Plan can require biosimilar use at initiation, but mid-treatment forced switches face higher appeal-reversal rates when the chart documents a stable patient, a defined transition-of-care concern, or prescriber "dispense-as-written" intent supported by a clinical rationale (immunogenicity history, nocebo response in prior switches, narrow therapeutic window). Cite the FDA Purple Book interchangeability designation when arguing the switch — interchangeable biosimilars permit pharmacy substitution; non-interchangeable biosimilars do not. Pharmacy-benefit handling is routed through UPMC Pharmacy Network (in-house, integrated payer-provider). External-review escalation for UPMC Health Plan fully-insured policies sits with the PA insurance department.
How do I prep for a peer-to-peer with UPMC Health Plan on TRASTUZUMAB (Herceptin)?
Lead with the FDA-approved indication and the specific clinical criteria the policy lists. Have the patient's chart open, document number, and policy URL on screen. State your name and credentials, the policy number, the indication, and the documented failures of step-therapy alternatives. Keep notes — if the P2P reviewer overturns, get the decision in writing.
Related PA criteria
Generate the TRASTUZUMAB (Herceptin) PA packet
Open ApprovalHelp — generate a TRASTUZUMAB (Herceptin) prior-auth packet tailored to UPMC Health Plan's criteria, with prescriber attestation and step-therapy documentation pre-filled.
Get started →Contact: hello@approvalhelp.com